Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.
Journal: European urology oncology
Published: March 12, 2025
Enriched class II HLA inherence in patients with checkpoint inhibitor-associated bullous pemphigoid.
Enriched class II HLA inherence in patients with checkpoint inhibitor-associated bullous pemphigoid.
Journal: International journal of dermatology
Published: October 10, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2024
Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
Journal: Translational cancer research
Published: May 05, 2024
PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
Journal: The Prostate
Published: January 28, 2024
Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.
Journal: Translational cancer research
Published: January 16, 2024
HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment.
Journal: Frontiers in medicine
Published: September 05, 2023
Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.
Journal: Frontiers in transplantation
Published: August 30, 2023
Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
Journal: Current urology reports
Published: March 13, 2023
Top Ten Tips Palliative Care Clinicians Should Know About Urological Care.
Journal: Journal of palliative medicine
Published: December 29, 2022
Virtual Tumor Board Increases Provider Attendance and Case Presentations.
Journal: JCO oncology practice
Published: August 08, 2022
Last Updated: 09/26/2026